Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of Americans will be obese. But the reality  is, it’s not just Americans.   According ...

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

( NewsNation) — The National Institute for Health and Care Excellence is calling on healthcare services to offer structured ...

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be unaffected.

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Republican leaders pushed back on the DHHS approach. They also tied the dispute to broader state budget negotiations.

An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...

Trump administration demands lower U.S. prices on drugs like Mounjaro, forcing the pharmaceutical company to raise them in ...